Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Fondaparinux sodium: A selective inhibitor of factor Xa
Autore:
Bauer, KA;
Indirizzi:
VA Boston Healthcare Syst, Hematol Sect, Boston, MA 02215 USA VA Boston Healthcare Syst Boston MA USA 02215 Sect, Boston, MA 02215 USA Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA Beth Israel Deaconess Med Ctr Boston MA USA 02215 r, Boston, MA 02215 USA
Titolo Testata:
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
fascicolo: 21, volume: 58, anno: 2001, supplemento:, 2
pagine: S14 - S17
SICI:
1079-2082(20011101)58:21<S14:FSASIO>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
SYNTHETIC PENTASACCHARIDE; ANTITHROMBIN-III; HIGH-AFFINITY; HEPARIN; THROMBIN; THROMBOCYTOPENIA; GENERATION; ABSENCE;
Keywords:
anticoagulants; duration of action; mechanism of action; Org-31540; pharmacokinetics; SR-90107A; thromboembolism; toxicity;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
15
Recensione:
Indirizzi per estratti:
Indirizzo: Bauer, KA VA Boston Healthcare Syst, Hematol Sect, 330 Brookline Ave, Boston, MA 02215 USA VA Boston Healthcare Syst 330 Brookline Ave Boston MA USA 02215
Citazione:
K.A. Bauer, "Fondaparinux sodium: A selective inhibitor of factor Xa", AM J HEAL S, 58(21), 2001, pp. S14-S17

Abstract

The pharmacology and mechanism of action of fondaparinux sodium are described. Fondaparinux sodium is the first agent of a new class of anticoagulants that selectively target factor Xa. It has a linear, dose-dependent pharmacokinetic profile, which provides a highly predictable response. It is 100% bioavailable, has a rapid onset of action, and has a half-life of 14 to 16 hours, allowing for sustained antithrombotic activity over a 24-hour period. The drug does not affect prothrombin time or activated partial thromboplastin time, nor does it affect platelet function or aggregation. Studies in patients with confirmed heparin-induced thrombocytopenia demonstrate that the drug is not associated with in vitro cross-reactivity to heparin antibodies. Fondaparinux sodium appears to meet the criteria for an ideal antithrombotic agent: equal or better effectiveness than currently available agents, a low bleeding risk, no need for laboratory monitoring, and once-daily administration.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 06:46:02